QS

QuantumScape's stock (QS) has experienced significant volatility and a general decline over the past six months, retreating approximately 29% over 90 days, 54% year-to-date, and 63% over one year, trading near its 52-week low of $4.77. Key events include a multi-year joint research agreement with Honda R&D in June 2026, which initially boosted shares as a validation point. In July 2026, Q2 earnings reported progress on customer billings and pilot production, but shares fell due to continued large losses ($98.2 million GAAP net loss) and the long path to commercialization. In September 2026, the company pushed its full commercialization target to 2029 and shifted towards licensing deals, contributing to investor pressure. Insider selling, totaling over $2 million in the past three months, including the CTO liquidating shares, also indicated cautious sentiment. Analyst consensus remains cautious with a "Reduce" rating and an average price target of $6.66, highlighting the stock's high-risk nature.